{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:22:20Z","timestamp":1792167740181,"version":"4.4.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["DT23\/00087"],"award-info":[{"award-number":["DT23\/00087"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005053","name":"Biomedical Research Network Centre of Bioengineering Biomaterials and Nanomedicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI18\/00252"],"award-info":[{"award-number":["PI18\/00252"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011597","name":"Conselleria de Sanitat Universal i Salut P\u00fablica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011597","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"Center for International Business Education and Research, University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["CIAICO23\/210"],"award-info":[{"award-number":["CIAICO23\/210"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["ACIF\/2021\/430"],"award-info":[{"award-number":["ACIF\/2021\/430"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.biopha.2025.117962","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:23:54Z","timestamp":1741699434000},"page":"117962","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy"],"prefix":"10.1016","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-7112","authenticated-orcid":false,"given":"Sheyla","family":"Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idoia","family":"Gallego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Olivares-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Puras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma Carmen","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Salom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Pedraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.117962_bib1","unstructured":"RetNet, Retinal information Network. [Online]. Available: \u3008https:\/\/retnet.org\u3009."},{"issue":"8","key":"10.1016\/j.biopha.2025.117962_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24087481","article-title":"Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/humu.23903","article-title":"A nationwide genetic analysis of inherited retinal diseases in Israel as assessed by the Israeli inherited retinal disease consortium (IIRDC)","volume":"41","author":"Sharon","year":"2020","journal-title":"Hum. Mutat."},{"issue":"10","key":"10.1016\/j.biopha.2025.117962_bib4","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ophtha.2020.04.008","article-title":"Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom","volume":"127","author":"Pontikos","year":"2020","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.biopha.2025.117962_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/ajmg.c.31843","article-title":"Genetic testing for inherited eye conditions in over 6,000 individuals through the eyeGENE network","volume":"184","author":"Goetz","year":"2020","journal-title":"Am. J. Med. Genet. C. Semin. Med. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib6","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41598-021-81093-y","article-title":"Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications","volume":"11","author":"Perea-Romero","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2025.117962_bib7","doi-asserted-by":"crossref","first-page":"1059947","DOI":"10.3389\/fimmu.2022.1059947","article-title":"Neuroinflammation in retinitis pigmentosa: therapies targeting the innate immune system","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12974-014-0172-9","article-title":"Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina","volume":"11","author":"Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara","year":"2014","journal-title":"J. Neuroinflamm."},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22042096","article-title":"Retinal inflammation, cell death and inherited retinal dystrophies","volume":"22","author":"Olivares-Gonz\u00e1lez","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"March","key":"10.1016\/j.biopha.2025.117962_bib10","first-page":"1","article-title":"NUTRARET: effect of 2-year nutraceutical supplementation on redox status and visual function of patients with retinitis pigmentosa: a randomized, double-blind, placebo-controlled trial","volume":"9","author":"Olivares-Gonz\u00e1lez","year":"2022","journal-title":"Front. Nutr."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib11","doi-asserted-by":"crossref","first-page":"11764","DOI":"10.1038\/srep11764","article-title":"Adalimumab reduces photoreceptor cell death in a mouse model of retinal degeneration","volume":"5","author":"Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.117962_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (Tnf-\u03b1) in autoimmune disease and current tnf-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.117962_bib13","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.ophtha.2018.02.020","article-title":"Successful optimization of adalimumab therapy in refractory uveitis due to Beh\u00e7et\u2019s disease","volume":"125","author":"Mart\u00edn-Varillas","year":"2018","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.biopha.2025.117962_bib14","first-page":"13839","article-title":"Intravitreal administration of adalimumab delays retinal degeneration in rd10 mice","volume":"34","author":"Olivares-Gonz\u00e1lez","year":"2020","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"7","key":"10.1016\/j.biopha.2025.117962_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103332","article-title":"Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders","volume":"22","author":"De Stefano","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041094","article-title":"Overcoming treatment challenges in posterior segment diseases with biodegradable nano-based drug delivery systems","volume":"15","author":"Wu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2025.117962_bib17","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-016-0339-2","article-title":"A comprehensive insight on ocular pharmacokinetics","volume":"6","author":"Agrahari","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"7","key":"10.1016\/j.biopha.2025.117962_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15071862","article-title":"Innovative strategies for drug delivery to the ocular posterior segment","volume":"15","author":"Gabai","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3797\/scipharm.1105-09","article-title":"Functions of lipids for enhancement of oral bioavailability of poorly water-soluble drugs","volume":"79","author":"Nanjwade","year":"2011","journal-title":"Sci. Pharm."},{"issue":"Sep","key":"10.1016\/j.biopha.2025.117962_bib20","article-title":"Nanostructured lipid carriers: promising drug delivery systems for future clinics","volume":"12","author":"Beloqui","year":"2015","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"7","key":"10.1016\/j.biopha.2025.117962_bib21","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1039\/D0BM01599G","article-title":"Dasatinib loaded nanostructured lipid carriers for effective treatment of corneal neovascularization","volume":"9","author":"Li","year":"2021","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/10717544.2022.2048134","article-title":"Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study","volume":"29","author":"Luo","year":"2022","journal-title":"Drug Deliv."},{"issue":"7","key":"10.1016\/j.biopha.2025.117962_bib23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/10837450.2019.1616755","article-title":"Thermosensitive hydrogel containing sertaconazole loaded nanostructured lipid carriers for potential treatment of fungal keratitis","volume":"24","author":"Tavakoli","year":"2019","journal-title":"Pharm. Dev. Technol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117962_bib24","first-page":"412","article-title":"Design of besifloxacin HCl-loaded nanostructured lipid carriers: in vitro and ex vivo evaluation","volume":"38","author":"Polat","year":"2022","journal-title":"J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.117962_bib25","article-title":"Nanostructured lipid carrier-loaded in situ gel for ophthalmic drug delivery: preparation and in vitro characterization studies","author":"Sabale","year":"2024","journal-title":"Pharm. Nanotechnol."},{"key":"10.1016\/j.biopha.2025.117962_bib26","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2020.05.017","article-title":"Design of ocular drug delivery platforms and in vitro - in vivo evaluation of riboflavin to the cornea by non-interventional (epi-on) technique for keratoconus treatment","volume":"324","author":"Aytekin","year":"2020","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14010090","article-title":"Lipid Nanoparticles for the Posterior Eye Segment","volume":"14","author":"Bonilla","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.117962_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119831","article-title":"Cutting-edge advances in therapy for the posterior segment of the eye: solid lipid nanoparticles and nanostructured lipid carriers","volume":"589","author":"de Oliveira","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.117962_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2174\/1389201025666230907145019","article-title":"Nanostructured lipid carriers mediated drug delivery to posterior segment of eye and their in-vivo successes","volume":"25","author":"Singh","year":"2024","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.biopha.2025.117962_bib30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejpb.2016.10.015","article-title":"Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues","volume":"109","author":"Balguri","year":"2016","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arb. fur Pharm. Verfahr. e. V."},{"issue":"15","key":"10.1016\/j.biopha.2025.117962_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26154673","article-title":"Lipid nanoparticles traverse non-corneal path to reach the posterior eye segment: in vivo evidence","volume":"26","author":"Puglia","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.biopha.2025.117962_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0887-2333(98)00085-X","article-title":"COLIPA validation project on in vitro eye irritation tests for cosmetic ingredients and finished products (phase I): the red blood cell test for the estimation of acute eye irritation potentials. Present status","volume":"13","author":"Pape","year":"1999","journal-title":"Toxicol. Vitr. Int. J. Publ. Assoc. BIBRA"},{"key":"10.1016\/j.biopha.2025.117962_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111912","article-title":"Impact of macroporous silica nanoparticles at sub-50nm on bio-behaviors and biosafety in drug-resistant cancer models","volume":"206","author":"Xu","year":"2021","journal-title":"Colloids Surf. B. Biointerfaces"},{"issue":"2","key":"10.1016\/j.biopha.2025.117962_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17435390.2017.1292371","article-title":"Biocompatibility and characterization of polyglycerol-based thermoresponsive nanogels designed as novel drug-delivery systems and their intracellular localization in keratinocytes","volume":"11","author":"Gerecke","year":"2017","journal-title":"Nanotoxicology"},{"key":"10.1016\/j.biopha.2025.117962_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.exer.2013.03.015","article-title":"Phosphodiesterase inhibition induces retinal degeneration, oxidative stress and inflammation in cone-enriched cultures of porcine retina","volume":"111","author":"Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara","year":"2013","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.biopha.2025.117962_bib36","series-title":"Ocular Pharmacokinetics BT - Pharmacology of the Eye","first-page":"19","author":"Maurice","year":"1984"},{"issue":"3","key":"10.1016\/j.biopha.2025.117962_bib37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0378-5173(90)90215-P","article-title":"Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits","volume":"61","author":"Urtti","year":"1990","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.117962_bib38","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40662-023-00334-5","article-title":"Anti-inflammatory and antioxidative effects of gallic acid on experimental dry eye: in vitro and in vivo studies","volume":"10","author":"Li","year":"2023","journal-title":"Eye Vis."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12010098","article-title":"An SPM-enriched marine oil supplement shifted microglia polarization toward M2, ameliorating retinal degeneration in rd10 mice","volume":"12","author":"Olivares-Gonz\u00e1lez","year":"2022","journal-title":"Antioxidants"},{"issue":"5","key":"10.1016\/j.biopha.2025.117962_bib41","first-page":"2438","article-title":"HIF-1\u03b1 stabilization reduces retinal degeneration in a mouse model of retinitis pigmentosa","volume":"32","author":"Olivares-Gonz\u00e1lez","year":"2018","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2025.117962_bib42","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.addr.2006.07.022","article-title":"Industrial perspective in ocular drug delivery","volume":"58","author":"Ali","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.117962_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/scipharm86020016","article-title":"Ocular delivery system for propranolol hydrochloride based on nanostructured lipid carrier","volume":"86","author":"Sharif Makhmal Zadeh","year":"2018","journal-title":"Sci. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.117962_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10020057","article-title":"Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems","volume":"10","author":"Danaei","year":"2018","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2025.117962_bib45","doi-asserted-by":"crossref","DOI":"10.1088\/1741-2552\/aca8ce","article-title":"HArtMuT-modeling eye and muscle contributors in neuroelectric imaging","volume":"19","author":"Harmening","year":"2022","journal-title":"J. Neural Eng."},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib46","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1081\/PDT-100102035","article-title":"Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution","volume":"5","author":"Klang","year":"2000","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.biopha.2025.117962_bib47","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2147\/IJN.S126199","article-title":"Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone","volume":"12","author":"Ban","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2025.117962_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.eurpolymj.2019.109353","article-title":"Role of particle shape on efficient and organ-based drug delivery","volume":"122","author":"Nejati","year":"2020","journal-title":"Eur. Polym. J."},{"issue":"36","key":"10.1016\/j.biopha.2025.117962_bib49","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.2174\/1381612821666150923095155","article-title":"Nanoparticles in ocular drug delivery systems for topical administration: promises and challenges","volume":"21","author":"Almeida","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib50","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/2230-973X.167661","article-title":"Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs","volume":"5","author":"Khan","year":"2015","journal-title":"Int. J. Pharm. Investig."},{"key":"10.1016\/j.biopha.2025.117962_bib51","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3762\/bjnano.14.66","article-title":"Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies","volume":"14","author":"Muraca","year":"2023","journal-title":"Beilstein J. Nanotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016100","article-title":"TNF-\u03b1 contributes to caspase-3 independent apoptosis in neuroblastoma cells: role of NFAT","volume":"6","author":"\u00c1lvarez","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2025.117962_bib53","first-page":"551","article-title":"Relationship and improvement strategies between drug nanocarrier characteristics and hemocompatibility: what can we learn from the literature","volume":"16","author":"Guo","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.117962_bib54","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000499870","article-title":"Relationship between Serum Adalimumab Levels and Clinical Outcome in the Treatment of Inflammatory Bowel Disease","volume":"37","author":"Hinojosa","year":"2019","journal-title":"Dig. Dis."},{"key":"10.1016\/j.biopha.2025.117962_bib55","unstructured":"S. Malignancies, D. Glioblastoma, and R.A. Astrocytoma, This label may not be the latest approved by FDA. For current labeling information, please visit \u3008https:\/\/www.fda.gov\/drugsatfda\u3009 This label may not be the latest approved by FDA. For current labeling information, please visit \u3008https:\/\/www.fda.gov\/drugsa\u3009. 2019."},{"issue":"3","key":"10.1016\/j.biopha.2025.117962_bib56","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/08982104.2016.1224899","article-title":"Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy","volume":"27","author":"Fu","year":"2017","journal-title":"J. Liposome Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.117962_bib57","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1517\/17425247.2015.1059419","article-title":"Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis","volume":"12","author":"\u00dcst\u00fcnda\u011f-Okur","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/11206721231174653","article-title":"Recent advances in nanotechnology for the treatment of fungal keratitis","volume":"34","author":"Zhang","year":"2024","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2025.117962_bib59","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ejpb.2022.02.010","article-title":"Lactoferrin-loaded nanostructured lipid carriers (NLCs) as a new formulation for optimized ocular drug delivery","volume":"172","author":"Varela-Fern\u00e1ndez","year":"2022","journal-title":"Eur. J. Pharm. Biopharm. Off. J. Arb. fur Pharm. Verfahr. e. V."},{"key":"10.1016\/j.biopha.2025.117962_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124222","article-title":"Novel nanostructured lipid carriers loading Apigenin for anterior segment ocular pathologies","volume":"658","author":"Bonilla-Vidal","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib61","first-page":"394","article-title":"Feasibility of drug delivery to the eye\u2019s posterior segment by topical instillation of PLGA nanoparticles","volume":"12","author":"Tahara","year":"2017","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/10717544.2019.1571122","article-title":"A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye","volume":"26","author":"Li","year":"2019","journal-title":"Drug Deliv."},{"issue":"8","key":"10.1016\/j.biopha.2025.117962_bib63","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3109\/10837450.2015.1089897","article-title":"Modified NLC-loaded coumarin for pharmaceutical applications: the improvement of physical stability and controlled release profile","volume":"21","author":"Iemsam-Arng","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.biopha.2025.117962_bib64","series-title":"Adler\u2019s Physiology of the Eye: Expert Consult - Online and Print","author":"Levin","year":"2011"},{"issue":"2","key":"10.1016\/j.biopha.2025.117962_bib65","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jps.22784","article-title":"Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels","volume":"101","author":"Gonzalez-Mira","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.117962_bib66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.colsurfb.2019.01.018","article-title":"Penetration of Nile red-loaded nanostructured lipid carriers (NLCs) across the porcine cornea","volume":"176","author":"Niamprem","year":"2019","journal-title":"Colloids Surf. B. Biointerfaces"},{"issue":"4","key":"10.1016\/j.biopha.2025.117962_bib67","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/03639045.2012.665460","article-title":"Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir","volume":"39","author":"Seyfoddin","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.biopha.2025.117962_bib68","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.2147\/IJN.S360740","article-title":"Dual Drug Loaded Lipid Nanocarrier Formulations for Topical Ocular Applications","volume":"17","author":"Youssef","year":"2022","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.biopha.2025.117962_bib69","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.immuni.2023.12.002","article-title":"Trem2 expression in microglia is required to maintain normal neuronal bioenergetics during development","volume":"57","author":"Tagliatti","year":"2024","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2025.117962_bib70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41419-023-05735-x","article-title":"TREM2 deficiency in microglia accelerates photoreceptor cell death and immune cell infiltration following retinal detachment","volume":"14","author":"Zhou","year":"2023","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.biopha.2025.117962_bib71","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41419-024-07002-z","article-title":"TREM2-dependent activation of microglial cell protects photoreceptor cell during retinal degeneration via PPAR\u03b3 and CD36","volume":"15","author":"Zhou","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2025.117962_bib72","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fnana.2017.00077","article-title":"Microglia polarization with M1\/M2 phenotype changes in rd1 mouse model of retinal degeneration","volume":"11","author":"Zhou","year":"2017","journal-title":"Front. Neuroanat."},{"issue":"18","key":"10.1016\/j.biopha.2025.117962_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814236","article-title":"A distinct microglial cell population expressing both CD86 and CD206 constitutes a dominant type and executes phagocytosis in two mouse models of retinal degeneration","volume":"24","author":"Zhang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.117962_bib74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117962_bib75","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.7150\/thno.54004","article-title":"Exosome-inflammasome crosstalk and their roles in inflammatory responses","volume":"11","author":"Noonin","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2025.117962_bib76","article-title":"Inflammasome signaling: a novel paradigm of hub platform in innate immunity for cancer immunology and immunotherapy","volume":"12","author":"Li","year":"2021","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2025.117962_bib77","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/hmg\/ddw029","article-title":"NLRP3 inflammasome activation drives bystander cone photoreceptor cell death in a P23H rhodopsin model of retinal degeneration","volume":"25","author":"Viringipurampeer","year":"2016","journal-title":"Hum. Mol. Genet."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:51:30Z","timestamp":1762311090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225001568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":77,"alternative-id":["S0753332225001568"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117962","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninvasive ocular delivery of adalimumab-loaded nanostructured lipid carriers for targeted retinitis pigmentosa therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117962","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117962"}}